Skip to main content
Erschienen in: Lifetime Data Analysis 4/2020

03.03.2020

Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study

verfasst von: Qingxia Chen, Fan Zhang, Ming-Hui Chen, Xiuyu Julie Cong

Erschienen in: Lifetime Data Analysis | Ausgabe 4/2020

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Treatment switching frequently occurs in clinical trials due to ethical reasons. Intent-to-treat analysis without adjusting for switching yields biased and inefficient estimates of the treatment effects. In this paper, we propose a class of semiparametric semi-competing risks transition survival models to accommodate two-way time-varying switching. Theoretical properties of the proposed method are examined. An efficient expectation–maximization algorithm is derived to obtain maximum likelihood estimates and model diagnostic tools. Existing software is used to implement the algorithm. Simulation studies are conducted to demonstrate the validity of the model. The proposed method is further applied to data from a clinical trial with patients having recurrent or metastatic squamous-cell carcinoma of head and neck.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA (2014) Introduction to smart designs for the development of adaptive interventions: with application to weight loss research. Transl Behav Med 4(3):260–274CrossRef Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA (2014) Introduction to smart designs for the development of adaptive interventions: with application to weight loss research. Transl Behav Med 4(3):260–274CrossRef
Zurück zum Zitat Branson M, Whitehead J (2002) Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 21:2449–63CrossRef Branson M, Whitehead J (2002) Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 21:2449–63CrossRef
Zurück zum Zitat Chen Q, Zeng D, Ibrahim JG, Chen MH, Pan Z, Xue X (2015) Quantifying the average of the time-varying hazard ratio via a class of transformations. Lifetime Data Anal 21(2):259–279MathSciNetCrossRef Chen Q, Zeng D, Ibrahim JG, Chen MH, Pan Z, Xue X (2015) Quantifying the average of the time-varying hazard ratio via a class of transformations. Lifetime Data Anal 21(2):259–279MathSciNetCrossRef
Zurück zum Zitat Chen LW, Yavuz I, Cheng Y, Wahed AS (2018) Cumulative incidence regression for dynamic treatment regimens. Biostatistics Chen LW, Yavuz I, Cheng Y, Wahed AS (2018) Cumulative incidence regression for dynamic treatment regimens. Biostatistics
Zurück zum Zitat Ibrahim JG, Lipsitz SR, Chen MH (1999) Missing covariates in generalized linear models when the missing data mechanism is nonignorable. J R Stat Soc Ser B 61:173–190MathSciNetCrossRef Ibrahim JG, Lipsitz SR, Chen MH (1999) Missing covariates in generalized linear models when the missing data mechanism is nonignorable. J R Stat Soc Ser B 61:173–190MathSciNetCrossRef
Zurück zum Zitat Ibrahim JG, Chu H, Chen MH (2012) Missing data in clinical studies: issues and methods. J Clin Oncol 30(26):3297–3303CrossRef Ibrahim JG, Chu H, Chen MH (2012) Missing data in clinical studies: issues and methods. J Clin Oncol 30(26):3297–3303CrossRef
Zurück zum Zitat Latimer NR, Abrams KR (2014) NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. School of Health and Related Research, University of Sheffield, Sheffield, p b12 Latimer NR, Abrams KR (2014) NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. School of Health and Related Research, University of Sheffield, Sheffield, p b12
Zurück zum Zitat Lin D (1991) Goodness-of-fit analysis for the Cox regression model based on a class of parameter estimators. J Am Stat Assoc 86(415):725–728MathSciNetCrossRef Lin D (1991) Goodness-of-fit analysis for the Cox regression model based on a class of parameter estimators. J Am Stat Assoc 86(415):725–728MathSciNetCrossRef
Zurück zum Zitat Louis TA (1982) Finding the observed information matrix when using the em algorithm. J R Stat Soc Ser B (Methodological) 44(2):226–233MathSciNetMATH Louis TA (1982) Finding the observed information matrix when using the em algorithm. J R Stat Soc Ser B (Methodological) 44(2):226–233MathSciNetMATH
Zurück zum Zitat Luo X, Li M, Wu C, Xu Q, Chen G, Dornseif BE, Renschler MF, Koch G (2016) A proposed approach for analyzing post-study therapy effect in survival analysis. J Biopharm Stat 26(4):790–800CrossRef Luo X, Li M, Wu C, Xu Q, Chen G, Dornseif BE, Renschler MF, Koch G (2016) A proposed approach for analyzing post-study therapy effect in survival analysis. J Biopharm Stat 26(4):790–800CrossRef
Zurück zum Zitat Machiels JPH, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594CrossRef Machiels JPH, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594CrossRef
Zurück zum Zitat Marcus SM, Gibbons RD (2001) Estimating the efficacy of receiving treatment in randomized clinical trials with noncompliance. Health Serv Outcomes Res Methodol 2:247–58CrossRef Marcus SM, Gibbons RD (2001) Estimating the efficacy of receiving treatment in randomized clinical trials with noncompliance. Health Serv Outcomes Res Methodol 2:247–58CrossRef
Zurück zum Zitat Robins JM, Finkelstein DM (2000) Correcting for noncompliance and dependent censoring in an aids clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56(3):779–788CrossRef Robins JM, Finkelstein DM (2000) Correcting for noncompliance and dependent censoring in an aids clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56(3):779–788CrossRef
Zurück zum Zitat Robins JM, Tsiatis AA (1991) Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 20:2609–31CrossRef Robins JM, Tsiatis AA (1991) Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 20:2609–31CrossRef
Zurück zum Zitat Shao J, Chang M, Chow SC (2005) Statistical inference for cancer trials with treatment switching. Stat Med 24:1783–90MathSciNetCrossRef Shao J, Chang M, Chow SC (2005) Statistical inference for cancer trials with treatment switching. Stat Med 24:1783–90MathSciNetCrossRef
Zurück zum Zitat White IR (2006) Estimating treatment effects in randomized trials with treatment switching. Stat Med 25:1619–22CrossRef White IR (2006) Estimating treatment effects in randomized trials with treatment switching. Stat Med 25:1619–22CrossRef
Zurück zum Zitat White IR, Babiker AG, Walker S, Darbyshire JH (1999) Randomization-based methods for correcting for treatment changes: examples from the concorde trial. Stat Med 18(19):2617–2634CrossRef White IR, Babiker AG, Walker S, Darbyshire JH (1999) Randomization-based methods for correcting for treatment changes: examples from the concorde trial. Stat Med 18(19):2617–2634CrossRef
Zurück zum Zitat Zeng D, Lin DY (2010) A general asymptotic theory for maximum likelihood estimation in semiparametric regression models with censored data. Stat Sin 20:871–910MathSciNetMATH Zeng D, Lin DY (2010) A general asymptotic theory for maximum likelihood estimation in semiparametric regression models with censored data. Stat Sin 20:871–910MathSciNetMATH
Zurück zum Zitat Zeng D, Chen Q, Chen MH, Ibrahim JG et al (2012) Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. Biometrika 99(1):167–184MathSciNetCrossRef Zeng D, Chen Q, Chen MH, Ibrahim JG et al (2012) Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. Biometrika 99(1):167–184MathSciNetCrossRef
Zurück zum Zitat Zhang M, Wang Y (2012) Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. Biostatistics 13(4):625–636CrossRef Zhang M, Wang Y (2012) Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. Biostatistics 13(4):625–636CrossRef
Zurück zum Zitat Zhang M, Wang Y (2013) Adjusting for observational secondary treatments in estimating the effects of randomized treatments. Biostatistics 14(3):491–501CrossRef Zhang M, Wang Y (2013) Adjusting for observational secondary treatments in estimating the effects of randomized treatments. Biostatistics 14(3):491–501CrossRef
Zurück zum Zitat Zhang B, Tsiatis AA, Laber EB, Davidian M (2012) A robust method for estimating optimal treatment regimes. Biometrics 68(4):1010–1018MathSciNetCrossRef Zhang B, Tsiatis AA, Laber EB, Davidian M (2012) A robust method for estimating optimal treatment regimes. Biometrics 68(4):1010–1018MathSciNetCrossRef
Zurück zum Zitat Zhao YQ, Zeng D, Laber EB, Kosorok MR (2015) New statistical learning methods for estimating optimal dynamic treatment regimes. J Am Stat Assoc 110(510):583–598MathSciNetCrossRef Zhao YQ, Zeng D, Laber EB, Kosorok MR (2015) New statistical learning methods for estimating optimal dynamic treatment regimes. J Am Stat Assoc 110(510):583–598MathSciNetCrossRef
Metadaten
Titel
Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study
verfasst von
Qingxia Chen
Fan Zhang
Ming-Hui Chen
Xiuyu Julie Cong
Publikationsdatum
03.03.2020
Verlag
Springer US
Erschienen in
Lifetime Data Analysis / Ausgabe 4/2020
Print ISSN: 1380-7870
Elektronische ISSN: 1572-9249
DOI
https://doi.org/10.1007/s10985-020-09495-0

Weitere Artikel der Ausgabe 4/2020

Lifetime Data Analysis 4/2020 Zur Ausgabe